Harmony Biosciences (NASDAQ:HRMY – Get Rating) had its target price hoisted by investment analysts at Oppenheimer from $55.00 to $62.00 in a research report issued on Wednesday, The Fly reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s price objective would indicate a potential upside of 27.13% from the stock’s previous close.
Separately, Cantor Fitzgerald initiated coverage on shares of Harmony Biosciences in a report on Thursday, April 14th. They set an “overweight” rating and a $63.00 price target for the company.
NASDAQ:HRMY opened at $48.77 on Wednesday. The company has a 50-day moving average of $43.50 and a 200-day moving average of $42.85. The company has a market capitalization of $2.88 billion, a price-to-earnings ratio of 60.96 and a beta of 0.63. Harmony Biosciences has a 52 week low of $25.09 and a 52 week high of $54.00. The company has a debt-to-equity ratio of 0.89, a quick ratio of 4.88 and a current ratio of 4.96.
In other Harmony Biosciences news, CEO John C. Jacobs sold 25,000 shares of the firm’s stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $44.18, for a total value of $1,104,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jack Nielsen sold 1,027 shares of the firm’s stock in a transaction dated Monday, April 4th. The shares were sold at an average price of $50.00, for a total transaction of $51,350.00. The disclosure for this sale can be found here. Insiders have sold a total of 212,025 shares of company stock valued at $10,719,413 over the last three months. 34.70% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of HRMY. Renaissance Technologies LLC increased its position in Harmony Biosciences by 233.9% in the 3rd quarter. Renaissance Technologies LLC now owns 39,400 shares of the company’s stock valued at $1,510,000 after acquiring an additional 27,600 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in Harmony Biosciences in the 3rd quarter valued at about $1,395,000. Marshall Wace LLP acquired a new stake in Harmony Biosciences in the 3rd quarter valued at about $570,000. Man Group plc acquired a new stake in Harmony Biosciences in the 3rd quarter valued at about $239,000. Finally, Comerica Bank acquired a new stake in shares of Harmony Biosciences during the 3rd quarter worth approximately $3,934,000. Hedge funds and other institutional investors own 75.62% of the company’s stock.
About Harmony Biosciences (Get Rating)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
- Get a free copy of the StockNews.com research report on Harmony Biosciences (HRMY)
- Insiders are Loading Up on These 3 Pullbacks
- Guidewire Software Stock is Set to Rebound
- Acuity Brands, Inc Illuminates An Attractive Opportunity
- The Value Of High-Yielding Walgreens Boots Alliance Deepens
- Paychex Continues To Provide Steady And Predictable Results
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.